NAFLD in the 20’s. From Epidemiology to Management (PART - II)

Author(s): Amedeo Lonardo, Giovanni Targher

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 32 , 2020


Become EABM
Become Reviewer
Call for Editor

[1]
Tovoli F, Ferri S, Piscaglia F. Hepatocellular carcinoma in non alcoholic fatty liver disease. Curr Pharm Des 2020; 26(32): 3909-14.
[2]
Ballestri S, Tana C, Di Girolamo M, et al. Semi-quantitative ultrasonographic evaluation of NAFLD. Curr Pharm Des 2020; 26(32): 3915-27.
[3]
Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease. Curr Pharm Des 2020; 26(32): 3928-38.


free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 32
Year: 2020
Published on: 23 September, 2020
Page: [3908 - 3908]
Pages: 1
DOI: 10.2174/138161282632200811172901

Article Metrics

PDF: 16
HTML: 1